Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for IMA203CD8 (TCR Cell Therapy) in Synovial Sarcoma. The expected timing is based on the latest available company guidance and may change.
05/30/26:- NCT03686124 Ph1 synovial sarcoma ORR 67%, cORR 64%. Follow-up at RP2D planned H2 2026. 07/17/26:- ESMO 2026 Phase 1 IMA203CD8 results abstract Oct 19; oral Oct 23, 2026. 08/18/26:- Phase 1 synovial sarcoma activity was updated. Multi-tumor Phase 1 data will be presented at ESMO 2026.
Verification
Confirm timing and program details against the company announcement or filing.